StreetInsider.com News Articles

'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler

Wed, 04 Mar 2026 07:55:32 -0500

Piper Sandler analyst Allison Bratzel raised the price target on Scholar Rock (NASDAQ: SRRK) to $58.00 (from $51.00) while maintaining an Overweight rating.

The analyst commented: "Regulatory Interactions Bode Well for Near-Term SMA Launch; We are incrementally positive on SRRK shares following a Q425 update that increases our confidence in a relatively near-term apitegromab BLA resubmission and US launch. Specifically, recent FDA interactions with Catalent Indiana (fill-finish facility that caused last year's CRL), including a meeting and field visit, yielded no additional remediation requests. With routine manufacturing at the facility now underway, it sounds like the reinspection could come any day,

'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler

Wed, 04 Mar 2026 07:55:32 -0500

Piper Sandler analyst Allison Bratzel raised the price target on Scholar Rock (NASDAQ: SRRK) to $58.00 (from $51.00) while maintaining an Overweight rating.

Scholar Rock (SRRK) PT Raised to $58 at Citi

Wed, 04 Mar 2026 05:50:17 -0500

Citi analyst Geoff Meacham raised the price target on Scholar Rock (NASDAQ: SRRK) to $58.00 (from $55.00) while maintaining a Buy rating.

Form 8-K/A Scholar Rock Holding For: Mar 03

Tue, 03 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260303/26102254.html

Form 8-K/A Scholar Rock Holding For: Mar 03

Tue, 03 Mar 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260303/26102254.html

Scholar Rock (SRRK) PT Raised to $50 at Leerink Partners

Tue, 03 Mar 2026 16:10:57 -0500

Leerink Partners analyst Mani Foroohar raised the price target on Scholar Rock (NASDAQ: SRRK) to $50.00 (from $48.00) while maintaining a Outperform rating.

Scholar Rock (SRRK) PT Raised to $53 at Barclays

Tue, 03 Mar 2026 16:01:37 -0500

Barclays analyst Etzer Darout raised the price target on Scholar Rock (NASDAQ: SRRK) to $53.00 (from $52.00) while maintaining a Overweight rating.

The analyst commented, "SRRK reported FY25 earnings, ending the year with $367.6M in cash and equivalents. SRRK announced the entry into a new debt instrument that provides access to up to $550M in funding for the commercial launch of apitegromab. The first $100M of the instrument was used to retire its debt facility with Oxford Finance. SRRK has access to $100M in 1Q26, an additional $150M on FDA approval of apitegromab, and incremental facilities up to $200M upon mutual

Scholar Rock (SRRK) PT Raised to $53 at Barclays

Tue, 03 Mar 2026 16:01:37 -0500

Barclays analyst Etzer Darout raised the price target on Scholar Rock (NASDAQ: SRRK) to $53.00 (from $52.00) while maintaining a Overweight rating.

Scholar Rock (SRRK) PT Raised to $55 at Truist Securities

Tue, 03 Mar 2026 13:54:57 -0500

Truist Securities analyst Srikripa Devarakonda raised the price target on Scholar Rock (NASDAQ: SRRK) to $55.00 (from $44.00) while maintaining a Buy rating.

The analyst commented, "We remain Buyers of SRRK shares following today's EPS call where mgmt remains positive on the developments at Catalent and SRRK's ability to resubmit apitegromab's BLA in 2026, potentially supporting FDA approval and launch in YE2026, which would be upside to our base case of early 2027 launch. SRRK remains on track to submit an sBLA for its second fill-finish site later in 2026 that would provide redundancy to apitegromab manufacturing. SRRK secured up to

Scholar Rock (SRRK) PT Raised to $55 at Truist Securities

Tue, 03 Mar 2026 13:54:57 -0500

Truist Securities analyst Srikripa Devarakonda raised the price target on Scholar Rock (NASDAQ: SRRK) to $55.00 (from $44.00) while maintaining a Buy rating.

Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)

Tue, 03 Mar 2026 13:34:30 -0500

Raymond James analyst Martin Auster reiterated a Strong Buy rating and $53.00 price target on Scholar Rock (NASDAQ: SRRK).

The analyst comments "Balance sheet strengthened with new debt facility and potential PRV monetization. The company announced a debt financing agreement with Blue Owl Capital for up to ~ $550M. While ~$200M will be utilized immediately, an additional ~$150M will be available upon FDA approval of apitegromab, plus an optional ~$200M at the mutual consent of SRRK and Blue Owl. Moreover, mgmt expressed their openness to PRV monetization in the event of marketing authorization for apitegromab (~$200M value), providing further liquidity to

Scholar Rock (SRRK) PT Raised to $70 at BMO Capital

Tue, 03 Mar 2026 12:49:24 -0500

BMO Capital analyst Evan David Seigerman raised the price target on Scholar Rock (NASDAQ: SRRK) to $70.00 while maintaining a Outperform rating.

The analyst comments "Progress marches on as site re-inspection and potential approval nears. Tone from management reflects confidence that apitegromab's Catalent site re-inspection and review could be faster than some expected under a type II resubmission. On improved confidence in approval and now slightly higher pricing considerations for apitegromab, we move our target price to $70. While apitegromab's initial launch may be somewhat slowed by initial efforts to secure access, we do not see this as a long-term barrier

Form S-8 Scholar Rock Holding

Tue, 03 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260303/26096451.html

Form S-8 Scholar Rock Holding

Tue, 03 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260303/26096451.html

Form 10-K Scholar Rock Holding For: Dec 31

Tue, 03 Mar 2026 07:17:00 -0500

si-local-file:///var/storage/secattach/20260303/26096427.html

Form 10-K Scholar Rock Holding For: Dec 31

Tue, 03 Mar 2026 07:17:00 -0500

si-local-file:///var/storage/secattach/20260303/26096427.html

Form 8-K Scholar Rock Holding For: Mar 03

Tue, 03 Mar 2026 07:14:00 -0500

si-local-file:///var/storage/secattach/20260303/26096410.html

Form 8-K Scholar Rock Holding For: Mar 03

Tue, 03 Mar 2026 07:14:00 -0500

si-local-file:///var/storage/secattach/20260303/26096410.html

Scholar Rock Holding Corp. (SRRK) Tops Q4 EPS by 2c

Tue, 03 Mar 2026 07:02:28 -0500

Scholar Rock Holding Corp. (NASDAQ: SRRK) reported Q4 EPS of ($0.88), $0.02 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Scholar Rock Holding Corp. (SRRK) click here.

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)
FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA
Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana
Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany
Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)

FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA

Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana

Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany

Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)

FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA

Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana

Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany

Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)

FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA

Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana

Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany

Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)

FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA

Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana

Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany

Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tue, 03 Mar 2026 07:00:00 -0500

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)

FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA

Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana

Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany

Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization